UBS Group AG Grows Stock Position in Insulet Corporation $PODD

Key Points

• UBS Group AG increased its stake in Insulet by 13.1% in Q4 to 234,022 shares (an additional 27,079 shares), representing about a 0.33% ownership worth roughly $66.52 million.
• Insider buying: Director Michael R. Minogue purchased 2,030 shares at $246.23 each (~$499,847), raising his holdings to 17,483 shares (a 13.14% increase); insiders now own about 0.36% of the company.
• Financials and sentiment: Insulet beat Q1 estimates with $1.55 EPS vs. $1.48 expected and revenue of $783.8M (up 31.2% YoY), though several analysts have trimmed price targets and the consensus remains a "Moderate Buy" with an average target of $327.24 while shares trade well below their 52‑week high.

UBS Group AG lifted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 234,022 shares of the medical instruments supplier's stock after purchasing an additional 27,079 shares during the period. UBS Group AG owned about 0.33% of Insulet worth $66,518,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Munich Reinsurance Co Stock Corp in Munich purchased a new position in Insulet in the fourth quarter worth approximately $5,803,000. Generali Investments Management Co LLC lifted its stake in Insulet by 63.1% in the fourth quarter. Generali Investments Management Co LLC now owns 1,143 shares of the medical instruments supplier's stock worth $325,000 after acquiring an additional 442 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Insulet in the fourth quarter worth approximately $171,000. Geneos Wealth Management Inc. lifted its stake in Insulet by 4.9% in the fourth quarter. Geneos Wealth Management Inc. now owns 35,924 shares of the medical instruments supplier's stock worth $10,211,000 after acquiring an additional 1,664 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. AG lifted its stake in Insulet by 40.3% in the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 5,210 shares of the medical instruments supplier's stock worth $1,481,000 after acquiring an additional 1,497 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.36% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Rothschild & Co Redburn reaffirmed a "neutral" rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Raymond James Financial decreased their price target on Insulet from $385.00 to $355.00 and set an "outperform" rating for the company in a report on Thursday, February 19th. Zacks Research downgraded Insulet from a "strong-buy" rating to a "hold" rating in a report on Monday, January 5th. Canaccord Genuity Group decreased their price target on Insulet from $450.00 to $435.00 and set a "buy" rating for the company in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group decreased their price target on Insulet from $326.00 to $277.00 and set a "buy" rating for the company in a report on Wednesday, April 8th. Eighteen analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $327.24.

Insulet Trading Down 2.1%

Shares of Insulet stock opened at $171.39 on Tuesday. The company has a fifty day simple moving average of $216.37 and a 200-day simple moving average of $267.14. Insulet Corporation has a 12-month low of $158.35 and a 12-month high of $354.88. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The stock has a market cap of $11.87 billion, a price-to-earnings ratio of 48.97, a PEG ratio of 1.03 and a beta of 1.20.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business had revenue of $783.80 million during the quarter, compared to analysts' expectations of $768.31 million. During the same quarter in the prior year, the business posted $1.15 EPS. The company's revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities analysts forecast that Insulet Corporation will post 6.27 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.